title: Amylin exerts osteogenic actions with different efficacy depending on the diabetic status.
abstract: Amylin displays osteogenic features, but its role in diabetic osteopenia is unclear. We examined the possible osteogenic action of amylin infusion for 3days into fructose-induced insulin-resistant (IR) and streptozotocin-induced type 2 diabetic (T2D) and normal (N) rats. Amylin failed to affect glycaemia or parathyroid hormone levels in any group, but reduced hyperinsulinemia in IR rats. In N rats, amylin increased bone formation rate and reduced osteoclast surface and erosive surface in the femoral metaphysis, and increased osteoprotegerin (OPG)/receptor activator of NFκB ligand (RANKL) mRNA ratio in the tibia. In T2D rats, amylin normalized trabecular structure parameters and increased osteoblast number and osteocalcin (OC) expression in long bones. In contrast, in IR rats, no apparent osteogenic effect of amylin in the femur was observed, although both OC and OPG/RANKL ratio were increased in the tibia. Our findings demonstrate a different osteogenic efficacy of amylin in two diabetic settings.
authors.affiliation: Departamento de Metabolismo, Nutrición y Hormonas, Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, Madrid, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Gutiérrez-Rojas
authors.forename: D
authors.initials: D
authors.lastname: Lozano
authors.forename: B
authors.initials: B
authors.lastname: Nuche-Berenguer
authors.forename: P
authors.initials: P
authors.lastname: Moreno
authors.forename: A
authors.initials: A
authors.lastname: Acitores
authors.forename: I
authors.initials: I
authors.lastname: Ramos-Álvarez
authors.forename: A
authors.initials: A
authors.lastname: Rovira
authors.forename: A
authors.initials: A
authors.lastname: Novials
authors.forename: E
authors.initials: E
authors.lastname: Martín-Crespo
authors.forename: M L
authors.initials: ML
authors.lastname: Villanueva-Peñacarrillo
authors.forename: P
authors.initials: P
authors.lastname: Esbrit
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000209:etiology; D048909:Diabetes Complications / Q000188:drug therapy; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005269:Femur / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D015870:Gene Expression; D058228:Islet Amyloid Polypeptide / Q000008:administration & dosage*; D008297:Male; D015675:Osteocalcin / Q000235:genetics / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects*; D053244:Osteoprotegerin / Q000235:genetics / Q000378:metabolism; D053245:RANK Ligand / Q000235:genetics / Q000378:metabolism; D011859:Radiography; D051381:Rats; D017208:Rats, Wistar; D013977:Tibia / Q000187:drug effects / Q000378:metabolism
chemical_list: D050071:Bone Density Conservation Agents; D058228:Islet Amyloid Polypeptide; D053244:Osteoprotegerin; D053245:RANK Ligand; D015675:Osteocalcin